Skip to main content

MYL Competitors

profileAnalyst coverage5 yr. financialspremium researchdividendsadv. chartsearningsoptionsprice historyeventsinsiders

Viatris, Inc. News

Biogen Beats Third-Quarter Earnings, Cuts Guidance

Drugmaker Biogen's third-quarter results feel the effect of generic versions of its multiple sclerosis treatment.

Mylan Will Buy Aspen Pharmacare's Thrombosis Business

Mylan will acquire drugmaker Aspen Pharmacare's European thrombosis business for $757 million.

Gold, Moderna, Qualtrics, Coronavirus: 5 Things You Must Know

Gold surges to an all-time high amid worsening U.S.-China tensions; Wall Street prepares for a week heavy on tech earnings; Moderna secures an additional $472 million to develop a coronavirus vaccine.

Biogen Stock Off After Barclays Downgrade on Patent Ruling

Biogen is downgraded to equal weight by Barclays, which cited an adverse MS-drug patent ruling.

Biogen Loses Court Decision to Mylan Over Multiple Sclerosis Drug

A U.S. District Court judge rules that Mylan proved claims for Biogen’s patent for Tecfidera are invalid for 'lack of written description.'

Breaking News

Morgan Stanley Stock Leads Gains As Banks Boost Dividends After Fed Stress Tests

Morgan Stanley, Wells Fargo, Bank of America and Goldman Sachs will lift their quarterly dividend, while JPMorgan will hold its steady following last week's Fed stress tests.

Nike Stock Slides As As Margin Pressures, China Worries Offset Q4 Earnings Beat

"We think we're well positioned for growth in fiscal year 2023 ... having said that, we did take a cautious approach to Greater China," said CFO Matthew Friend.

Playtika Stock Surges On Report of Joffre Capital Interest in Online Casino Gaming Group

Axios reported late Monday that tech buyout group Joffre Capital is seeking a majority stake in the online casino video game group.

Walgreens Stock Slides As Group Scraps Plan to Sell UK-based Boots

"As a result of market instability ... no third party has been able to make an offer that adequately reflects the high potential value of Boots," Walgreens said.